Article

BCAN's First "Bladder Cancer Matters" Podcast is Now Available

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

In this episode, Rick and Dr. Kamat discuss what BCG is, how it is used, why there is a BCG shortage and what some therapeutic alternatives are.

This episode is sponsored by FerGene, a new gene therapy company dedicated to creating and delivering innovative solutions for bladder cancer.

Click on this link to listen to the fascinating 30 minute conversation: https://bcan.org/what-up-with-bladder-cancer-and-bcg-with-dr-ashish-kamat/

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man.
Image of man with black hair.
Image of man.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Image of bald man.
Related Content
Image of bladder.
April 30th 2025

Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer

Jason M Broderick
Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety: © stock.adobe.com.
April 28th 2025

Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer

Jax DiEugenio
Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Illustration of bladder.
April 22nd 2025

Imfinzi Combination Shows Efficacy in Bladder Cancer Treatment

Ryan Scott
Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder cancer, based on the NIAGARA trial.
Image of bladder.
April 17th 2025

Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer

Alex Biese
Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.